Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

BACKGROUND: Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R. This multicenter phase 1/2 study evaluated the maximum tolerated dose (MTD), safety, and clinical activity of pacritinib in patients with myelofibrosis (MF) and other advanced my...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Hematol Oncol
Main Authors: Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. Joachim
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5146859/
https://ncbi.nlm.nih.gov/pubmed/27931243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0367-x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki